Učitavanje...
Apatinib monotherapy for advanced non‐small cell lung cancer after the failure of chemotherapy or other targeted therapy
BACKGROUND: Apatinib, a small‐molecule inhibitor of vascular endothelial growth factor receptor 2 (VEGFR‐2), has proven to be effective and safe for treating patients with advanced gastric cancer after second‐line chemotherapy failure. As VEGFR‐2 targeted therapy has made encouraging progress for th...
Spremljeno u:
| Izdano u: | Thorac Cancer |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley & Sons Australia, Ltd
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6166085/ https://ncbi.nlm.nih.gov/pubmed/30126078 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12836 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|